Evidence map›Paper›PMID 35697384›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2022

The Pre-Existing Human Antibody Repertoire to Computationally Optimized Influenza H1 Hemagglutinin Vaccines.

Kaito Nagashima, John V Dzimianski, Julianna Han, Nada Abbadi, Aaron D Gingerich, Fredejah Royer, Sara O'Rourke, Giuseppe A Sautto, Ted M Ross, Andrew B Ward and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. mRNA Vaccines for Influenza: Hope for a Universal Vaccine?BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Kaito NagashimaDepartment of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA.ORCID 0000-0002-7501-6651
John V DzimianskiDepartment of Biomolecular Engineering, University of California Santa Cruz, Santa Cruz, CA.ORCID 0000-0002-2447-146X
Julianna HanDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA; and.ORCID 0000-0002-3402-2609
Nada AbbadiDepartment of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA.
Aaron D GingerichCenter for Vaccines and Immunology, College of Veterinary Medicine, University of Georgia, Athens, GA.
Fredejah RoyerCenter for Vaccines and Immunology, College of Veterinary Medicine, University of Georgia, Athens, GA.ORCID 0000-0003-3012-2431
Sara O'RourkeDepartment of Biomolecular Engineering, University of California Santa Cruz, Santa Cruz, CA.ORCID 0000-0001-8624-0483
Giuseppe A SauttoCenter for Vaccines and Immunology, College of Veterinary Medicine, University of Georgia, Athens, GA.ORCID 0000-0002-0273-2235
Ted M RossDepartment of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA.
Andrew B WardDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA; and.
Rebecca M DuBoisDepartment of Biomolecular Engineering, University of California Santa Cruz, Santa Cruz, CA.ORCID 0000-0003-4185-5673
Jarrod J MousaDepartment of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA; jarrod.mousa@uga.edu.ORCID 0000-0003-4709-2478
University of Georgia · USUniversity of California, Santa Cruz · USScripps Research Institute · US

Funding

COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH75N93019C00051 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAMMER, FLORIAN · 2019 to 2025
$105.4M
COVID Supplement - COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES,75N93019C00052 · NIAID · UNIVERSITY OF GEORGIA · PI ROSS, TED · 2019 to 2025
$74.6M
PREP at University of GeorgiaR25GM109435 · NIGMS · UNIVERSITY OF GEORGIA · PI DOLAN, ERIN L, KLONOWSKI, KIMBERLY D. · 2014 to 2024
$3.4M
Therapeutic antibodies to treat Pneumocystis pneumonia in a nonhuman primate model of HIV infectionK01OD026569 · OD · UNIVERSITY OF GEORGIA · PI MOUSA, JARROD · 2018 to 2020
$1.0M
An Octet Bio-layer Interferometer for Macromolecular Interaction Studies at UCSCS10OD027012 · OD · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI RUBIN, SETH MICHAEL · 2019 to 2019
$370k
NIAID NIH HHS 75N93019C00051NIAID NIH HHS 75N93019C00052NIGMS NIH HHS R25 GM109435NIH HHS K01 OD026569NIH HHS S10 OD027012
6 · The paper itself

Abstract

Computationally optimized broadly reactive Ag (COBRA) hemagglutinin (HA) immunogens have previously been generated for several influenza subtypes to improve vaccine-elicited Ab breadth. As nearly all individuals have pre-existing immunity to influenza viruses, influenza-specific memory B cells will likely be recalled upon COBRA HA vaccination. We determined the epitope specificity and repertoire characteristics of pre-existing human B cells to H1 COBRA HA Ags. Cross-reactivity between wild-type HA and H1 COBRA HA proteins P1, X6, and Y2 were observed for isolated mAbs. The mAbs bound five distinct epitopes on the pandemic A/California/04/2009 HA head and stem domains, and most mAbs had hemagglutination inhibition and neutralizing activity against 2009 pandemic H1 strains. Two head-directed mAbs, CA09-26 and CA09-45, had hemagglutination inhibition and neutralizing activity against a prepandemic H1 strain. One mAb, P1-05, targeted the stem region of H1 HA, but did not compete with a known stem-targeting H1 mAb. We determined that mAb P1-05 recognizes a recently discovered HA epitope, the anchor epitope, and we identified similar mAbs using B cell repertoire sequencing. In addition, the trimerization domain distance from HA was critical to recognition of this epitope by mAb P1-05, suggesting the importance of protein design for vaccine formulations. Overall, these data indicate that seasonally vaccinated individuals possess a population of functional H1 COBRA HA-reactive B cells that target head, central stalk, and anchor epitopes, and they demonstrate the importance of structure-based assessment of subunit protein vaccine candidates to ensure accessibility of optimal protein epitopes.

Indexed as

Antibodies, ViralHemagglutinin Glycoproteins, Influenza VirusInfluenza, HumanInfluenza VaccinesAntibodies, MonoclonalB-LymphocytesEpitopesHumansAntibodies, MonoclonalAntibodies, ViralEpitopesHemagglutinin Glycoproteins, Influenza VirusInfluenza Vaccines

Identifiers

PMID35697384
PMCPMC9246865
OpenAlexW4282918616

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.